Tech Support

TECHNICAL SUPPORT
+1.800.674.3430

This line is for technical support.
For General Enquiries please click General Contact

WEBINAR: Reversing Hypertriglyceridemia and Hepatic Steatosis in Dysmetabolic NHPs with a Controlled-Release Mitochondrial Protonophore (CRMP)

Wednesday August 14, 10:30 am EST

Presented by Dr Leigh Goedeke, Yale School of Medicine this webinar details using spontaneous NHP models of NAFLD and metabolic syndrome to assess a controlled-release mitochondrial protonophore (CRMP). Explore proof-of-concept data from these clinically relevant models, supporting the development of novel liver-targeted mitochondrial uncouplers to treat human NASH and T2D.

Screen Your I/O Agent Efficacy In Vivo with Our 6 Model Tumor Homograft Panel

The tumor homograft MuScreenTM is now available in a smaller panel, covering 6 different indications and with each model harboring clinically-relevant mutations. Screen your I/O agent efficacy in these fully immunocompetent models that have never been passaged in vitro.

NEW WHITE PAPER: How to Improve the Predictive Value of Preclinical Oncology Studies: Imaging Orthotopic Models

Explore the benefits of imaging orthotopic, metastatic models. Read our new White Paper to learn more about key model utilities for studying disease progression and metastasis, and for assessing novel agents for different disease stages.

ON DEMAND WEBINAR: Assessing Immunotherapy Toxicity in NHPs

Presented by Dr Thomas Scullion this webinar focuses on using NHPs for the preclinical assessment of immunotherapy toxicity. Explore how clinical trials are de-risked by evaluating immuno-safety early in drug discovery, and how to incorporate exploratory toxicology NHP studies into your preclinical programs.

New US Site Grand Opening Promotion - Free Arm on Syngeneic Studies until July 30th!

To celebrate the Grand Opening of our new San Diego site we're offering a free arm on subcutaneous syngeneic model studies. You can choose from any validated syngeneic model offered at our US location for studies with at least 5 arms and n=10/arm.

WHITE PAPER: Optimizing Translational IBD Capabilities How to Select the Right Preclinical Model

Explore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance.

ON DEMAND WEBINAR: Overcoming Challenges in NAFLD/NASH Preclinical Modeling

Presented by Dr Guodong Zhang this webinar focuses on new solutions to overcome preclinical NAFLD/NASH research challenges. Explore the pros and cons of a range of preclinical NASH models, as well as alternative liver disease evaluation methods, to help optimize and progress your drug development programs.

Download our ADA 2019 Posters

We presented posters on our unique translational NASH model at the ADA Scientific Sessions this year. Download our latest data on NASH induction in the dysmetabolic MS-NASH mouse (formerly FATZO), and accelerated disease induction resulting in a model featuring both severe fibrosis and dysmetabolism.

NEW WHITE PAPER: How to Leverage Tumor Models for Pancreatic Cancer Research

Explore advanced models and novel I/O technologies for pancreatic cancer research. Learn more about orthotopic tumor homografts, more accurately replicating PDAC TME in vivo for more clinically-relevant preclinical studies. Discover CAR-T cell therapy as a potential new treatment strategy for pancreatic cancer.

NEW WHITE PAPER: Key Applications of Syngeneic Models to Maximize I/O Translatability

Learn how to optimize syngeneic translatability through proof of concept and target engagement studies. Read our new White Paper to explore how panels of syngeneic models are used to evaluate new single agent and combination regimens, uncover biomarkers of I/O response, and discover common PD markers for predicting population response.

BREAKING NEWS: CrownBio and Hubrecht Organoid Technology Announce Strategic Partnership

Partnership combines breakthrough organoid technology with the world’s largest PDX collection to create a unique patient-derived translational research platform.

New Accelerated and Exacerbated Liver Fibrosis Model for NASH Preclinical Studies

Advance your NASH therapeutics with the inherently dysmetabolic, obese, and diabetic MS-NASH mouse (formerly FATZO). Learn more about standard NASH induction on Western diet plus fructose, as well as accelerated disease progression and exacerbated pathology with CCl4 administration. Explore new CCl4 data, including improved lipid profile and NAS score with OCA treatment.

ON DEMAND WEBINAR: How to Optimize Preclinical Diabetes Studies using Stress Free Methods in NHPs

Presented by Dr Andrew Puca this webinar focuses on novel techniques for optimizing preclinical diabetes research with spontaneously diabetic NHPs. Learn more about continuous glucose monitoring and the banana tolerance test, and how reducing invasiveness and stress leads to improved study data and clinical outcomes.

Clarity with
Crown

Recognize your next clinical candidate when you see it.

Our Translational Platforms enable our clients to identify the right patients for the right treatment. Having models which more accurately mimic human disease and population dynamics are key to successfully translating promising compounds into successful clinical candidates, whether treating Oncology or Diabetes related diseases.

Magnify your
insights

Understand the mechanisms of disease.

Our scientific acumen and experience will give you a deeper understanding of not just the pharmacological profile of your compound, but more importantly, a clear understanding of which compounds to progress into the clinic. Take a look at our publications to get a deeper understanding of the depth of our scientific expertise.

Begin with the
end insight

Connecting science to patients.

We help our clients solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease by answering some of the most challenging questions about human biology.

CVMD

Models of Obesity

obesity-img.jpg

CrownBio’s preclinical Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.

Learn More

Oncology

Oncology Databases

databases-img.jpg

Our unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.

Learn More

CVMD

Diabetes Models

oncoexpress-img.jpg

Models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for in vivo efficacy studies of antidiabetic agents.

Learn More

Latest from our Blog

July 19, 2019

Recapitulating Clinical Metastatic Events in Preclinical Mouse Models

Explore the preclinical mouse models that best recapitulate the progression of the clinical metastatic process.

Read More

July 19, 2019

Recapitulating Clinical Metastatic Events in Preclinical Mouse Models

Explore the preclinical mouse models that best recapitulate the progression of the clinical...

Read More

July 18, 2019

Tumor Organoids and the HUB Protocol Method

Review organoid culture techniques and applications, with a focus on tumor organoids developed...

Read More

July 9, 2019

CAR-T Cell Therapy for Pancreatic Cancer

Explore how CAR-T cell therapy is showing promise as a novel treatment strategy for pancreatic...

Read More

June 20, 2019

Modelling the Full Progression of Type 2 Diabetes | Q&A

Learn how we model the full progression of Type 2 diabetes with improved clinical relevance in...

Read More

June 13, 2019

Comparing Traditional Rodent Models for Metabolic Research

Explore the main features, advantages, and limitations of common rodent models used in...

Read More

Upcoming Events


July 16 - 18, 2019

7th Annual PREDiCT: Tumor Models Boston Summit

Boston, MA


July 31, 2019

Symposium: Biomedical Science Frontiers in Oncology Drug Discovery

Taipei, Taiwan


August 5 - 9, 2019

7th Annual Immuno-Oncology Summit 2019

Boston, MA


August 14, 2019

Webinar: Reversing Hypertriglyceridemia and Hepatic Steatosis in Dysmetabolic NHPs with a Controlled-Release Mitochondrial Protonophore (CRMP)


August 21, 2019

Seminar: JSR Life Sciences’ Integrated Oncology Platform for Biomarker and Companion Diagnostic Development

Fujisawa, Japan